Irritable bowel syndrome
Conditions
Interventions
Keishikashakuyakuto 7.5g/day, daily three times, for two months
Sponsors
Yokohama City University School of Medicine Department of Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1, The patients who meet the IBS criteria by ROMEIII 2, Patients who had past history of IBS and are going on medical treatment for more than 4 weeks before entry 3, Patients who can exhibit their consent in a document
Exclusion criteria
Exclusion criteria: 1,Patients who had history of gastrointestinal tract resection 2,Patients who have severe complications 3,Patients who have history of Kampo allergies 4,Patients who have history of lactose intolerance 5,Patients who had taken new drug therapy within 4 weeks before entry 6,Patients who had any change in types, dosage, or adiministration of their prescribed drugs within 4 weeks before entry 7,Patients who are or are going to be participating in other clinical studies 8,Patients who are pregnant or possibly pregnant 9,Patients who are judged as inadequately for study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The score of IBS-QOL at study entry and at the end of 2-months drug intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1,The rate of improvement of IBS-QOL score at the end of 2-months drug intervention 2,The rate of improvement of IBS-QOL score at the end of 2-months drug intervention according to type of IBS 3,The rate of improvement of IBS-SI score at the end of 2-months drug intervention 4,The score of IBS-SI at study entry and at the end of 2-months drug intervention 5,The rate of improvement of IBS-QOL score at the end of 1-months drug intervention | — |
Countries
Japan
Contacts
Public ContactFuyuki Akiko
Yokohama City University school of medicine Department of gastroenterology and hepatology
Outcome results
None listed